09/04/2026
Could your synthetic route benefit from an efficient approach to site-specific deuterium incorporation?
Process chemists developing deuterated APIs are often challenged to achieve selective deuterium incorporation while maintaining process efficiency and synthetic flexibility.
-d₃ has become an important reagent for site-specific deuterium incorporation through selective reduction chemistry, enabling streamlined preparation of deuterated intermediates and APIs.
As deuterated drug programs move toward clinical and commercial stages, project teams increasingly evaluate factors beyond reaction performance.
• Supply chain reliability
• Manufacturing scalability
• Regulatory readiness
• Long-term availability
These considerations can significantly influence development timelines and commercialization strategies.
At CIL, we believe deuterated reagents should not only support successful chemistry, but also successful scale-up.
📍 Meet our team at - CIL BOOTH 3F34, to discuss how ISOAPI-D™ can support your next generation of deuterated therapeutics.
For more information: https://technologies.isotope.com/